Published 2010 | Version v1
Miscellaneous Open

Dosimetric Studies in Normal Mice of 177Lu-DOTA-SP and 177Lu-DOTA-His2-MG

  • 1. Autoridad Regulatoria Nuclear, Buenos Aires (Argentina)
  • 2. Comision Nacional de Energia Atomica (Argentina)

Description

DOTA-Substance-P (SP) and DOTA-minigastrin (His2-MG) labeled with 177Lu could be used in peptide receptor radionuclide therapy (PRRT) for treatment of various tumour species. Biodistribution studies of both radiopharmaceuticals in normal mice were performed at different times. Absorbed doses in mouse organs were estimated and extrapolated to humans. Dosimetric calculations showed that kidneys received the highest dose, for both radiopharmaceuticals. The Maximum Tolerated Activity (MTA) of 177Lu-DOTA-SP that can be administered without kidney toxicity are 414 and 422 MBq/kg for the standard adult man and woman, respectively. In the same way, the MTA of 177Lu-DOTA-His2-MG are 488 and 518 MBq/kg for the standard adult man and woman, respectively. (authors)

Files

44096788.pdf

Files (222.3 kB)

Name Size Download all
md5:240999b82ed96ff769ccd0dc26d76478
222.3 kB Preview Download
Part of:
Technical Memory 2010. Nuclear Regulatory Authority

Additional details

Additional titles

Original title (Spanish)
Estudios dosimétricos en los ratones normales de

Publishing Information

Publisher
ARN
Imprint Place
Buenos Aires (Argentina)
Imprint Title
Technical Memory 2010. Nuclear Regulatory Authority
Imprint Pagination
228 p.
Journal Page Range
p. 141-145
Report number
INIS-AR-A--14

Conference

Title
International Symposium on Technetium and other Radiometals in Chemistry and Medicine
Dates
8-11 Sep 2010
Place
Bressanone, Bolzano (Italy)

Optional Information

Notes
2 refs., 1 figs., 2 tabs. Poster Imprint:Memoria Tecnica 2010. Autoridad Regulatoria Nuclear